25I-NBOH
From Wikipedia, the free encyclopedia
25I-NBOH
|
|
Systematic (IUPAC) name | |
2-((2-(4-iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol | |
Identifiers | |
CAS number | ? |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C17H20INO3 |
Mol. mass | 413.249 g/mol |
SMILES | & |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
25I-NBOH or N-(2-hydroxybenzyl)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminoethane is a derivative of the phenethylamine derived hallucinogen 2C-I, discovered in 2006 by a team at Purdue University. It acts as a potent agonist for the 5HT2A receptor with a Ki of 0.12nM at the human 5HT2A receptor, making it some 5x the potency of 2C-I itself. In vitro tests showed this compound acted as an agonist but animal studies have not been reported. Interestingly while the N-benzyl derivatives of 2C-I were significantly increased in potency compared to 2C-I, the N-benzyl derivatives of DOI were inactive.[1]
[edit] References
- ^ Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology. 2006 Dec;70(6):1956-64. PMID 17000863
|